A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh.

• Main Authors: Shyam Sundar (Author), Krishna Pandey (Author), Dinesh Mondal (Author), Major Madhukar (Author), Roshan Kamal Topno (Author), Ashish Kumar (Author), Vinod Kumar (Author), Deepak Kumar Verma (Author), Jaya Chakravarty (Author), Rahul Chaubey (Author), Poonam Kumari (Author), Md Utba Rashid (Author), Shomik Maruf (Author), Prakash Ghosh (Author), Sheeraz Raja (Author), Joelle Rode (Author), Margriet den Boer (Author), Pradeep Das (Author), Jorge Alvar (Author), Suman Rijal (Author), Fabiana Alves (Author)
• 格式: 圖書
• 出版: Public Library of Science (PLoS), 2024-06-01T00:00:00Z.
• 主題: article
• 在線閱讀: Connect to this object online.

<h4>Background</h4>In Southeast Asia, treatment is recommended for all patients with post-kala-azar dermal leishmaniasis (PKDL). Adherence to the first-line regimen, twelve weeks of miltefosine (MF), is low and ocular toxicity has been observed with this exposure period. We assessed the...